ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 277,77
-0,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Agios Pharmaceuticals Inc (AGIO)

  7. Agios Pharmaceuticals Inc (AGIO) Actualités

AGIO

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AGIO
DateHeureSourceTitreSymboleSociété
07/06/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
06/06/202415h00GlobeNewswire Inc.Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ETNASDAQ:AGIOAgios Pharmaceuticals Inc
06/06/202401h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
03/06/202412h30GlobeNewswire Inc.Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaNASDAQ:AGIOAgios Pharmaceuticals Inc
30/05/202422h05GlobeNewswire Inc.Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
28/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGIOAgios Pharmaceuticals Inc
28/05/202413h00GlobeNewswire Inc.Agios Announces $905 Million Purchase Agreement for Vorasidenib RoyaltyNASDAQ:AGIOAgios Pharmaceuticals Inc
14/05/202416h00GlobeNewswire Inc.Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressNASDAQ:AGIOAgios Pharmaceuticals Inc
06/05/202413h00GlobeNewswire Inc.Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
03/05/202413h00GlobeNewswire Inc.Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
02/05/202413h00GlobeNewswire Inc.Agios Reports Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
18/04/202413h00GlobeNewswire Inc.Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
09/04/202413h00GlobeNewswire Inc.Agios Publishes 2024 Environmental, Social and Governance (ESG) ReportNASDAQ:AGIOAgios Pharmaceuticals Inc
05/03/202413h00GlobeNewswire Inc.Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
22/02/202413h00GlobeNewswire Inc.Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
15/02/202416h33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AGIOAgios Pharmaceuticals Inc
15/02/202413h00GlobeNewswire Inc.Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AGIOAgios Pharmaceuticals Inc
14/02/202420h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGIOAgios Pharmaceuticals Inc
02/02/202413h00GlobeNewswire Inc.Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
08/01/202413h00GlobeNewswire Inc.Agios Announces Key Anticipated 2024 Milestones Across Rare Disease PortfolioNASDAQ:AGIOAgios Pharmaceuticals Inc
03/01/202412h30GlobeNewswire Inc.Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaNASDAQ:AGIOAgios Pharmaceuticals Inc
02/01/202413h00GlobeNewswire Inc.Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
10/12/202301h00GlobeNewswire Inc.Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and ExpositionNASDAQ:AGIOAgios Pharmaceuticals Inc
20/11/202313h00GlobeNewswire Inc.Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesNASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202314h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202314h05GlobeNewswire Inc.Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and ExpositionNASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202312h00GlobeNewswire Inc.Agios Reports Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
29/08/202313h00GlobeNewswire Inc.Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023NASDAQ:AGIOAgios Pharmaceuticals Inc
03/08/202312h35GlobeNewswire Inc.Agios Reports Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
03/08/202312h30GlobeNewswire Inc.Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia VeraNASDAQ:AGIOAgios Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AGIO

Dernières Valeurs Consultées

BITMOT
928042
Gs Group Tf 3% Ap32 Call...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés